JP2022526367A5 - - Google Patents
Info
- Publication number
- JP2022526367A5 JP2022526367A5 JP2021557778A JP2021557778A JP2022526367A5 JP 2022526367 A5 JP2022526367 A5 JP 2022526367A5 JP 2021557778 A JP2021557778 A JP 2021557778A JP 2021557778 A JP2021557778 A JP 2021557778A JP 2022526367 A5 JP2022526367 A5 JP 2022526367A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- lipocalin
- pharmaceutical product
- product according
- mutheine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826767P | 2019-03-29 | 2019-03-29 | |
| US62/826,767 | 2019-03-29 | ||
| EP19166435 | 2019-04-01 | ||
| EP19166435.8 | 2019-04-01 | ||
| EP19175818.4 | 2019-05-22 | ||
| EP19175818 | 2019-05-22 | ||
| EP19177568 | 2019-05-31 | ||
| EP19177568.3 | 2019-05-31 | ||
| EP19211404.9 | 2019-11-26 | ||
| EP19211404 | 2019-11-26 | ||
| PCT/EP2020/058637 WO2020201038A1 (en) | 2019-03-29 | 2020-03-27 | Inhaled administration of lipocalin muteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022526367A JP2022526367A (ja) | 2022-05-24 |
| JP2022526367A5 true JP2022526367A5 (enExample) | 2023-04-03 |
Family
ID=70292935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557778A Withdrawn JP2022526367A (ja) | 2019-03-29 | 2020-03-27 | リポカリンムテインの吸入投与 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220168387A1 (enExample) |
| EP (1) | EP3946417A1 (enExample) |
| JP (1) | JP2022526367A (enExample) |
| KR (1) | KR20210146999A (enExample) |
| CN (1) | CN113939307A (enExample) |
| AU (1) | AU2020253034A1 (enExample) |
| CA (1) | CA3127973A1 (enExample) |
| WO (1) | WO2020201038A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| KR20230121785A (ko) * | 2020-12-18 | 2023-08-21 | 아스트라제네카 에이비이 | 천식 치료용 리포칼린 뮤테인 건조 분말 제형 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5354934A (en) | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| WO2003029471A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7892827B2 (en) * | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| EP2046820B1 (en) | 2006-08-01 | 2010-10-20 | Pieris AG | Muteins of tear lipocalin and methods for obtaining the same |
| CN101932598B (zh) | 2008-01-30 | 2016-12-21 | 皮里斯股份公司 | 具有对人c-met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法 |
| RU2707126C2 (ru) * | 2009-12-07 | 2019-11-22 | Пирис Аг | МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2, hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ |
| PL2580236T3 (pl) * | 2010-06-08 | 2019-09-30 | Pieris Pharmaceuticals Gmbh | Muteiny lipokaliny łez wiążące IL-4 R alfa |
| EP3299386A1 (en) | 2010-08-16 | 2018-03-28 | Pieris Pharmaceuticals GmbH | Binding proteins for hepcidin |
| AU2011331232B2 (en) | 2010-11-15 | 2015-05-07 | Pieris Ag | Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3) |
| EP2646552B1 (en) | 2010-12-02 | 2017-07-05 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for ctla-4 |
| AU2012350654C1 (en) * | 2011-12-12 | 2018-05-10 | Pieris Ag | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation |
| EP3842058B1 (en) * | 2011-12-13 | 2023-08-23 | Pieris Pharmaceuticals GmbH | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
| MY175188A (en) * | 2012-01-09 | 2020-06-13 | Pieris Ag | Methods for preventing, treating or diagnosing disorders |
| US9522940B2 (en) * | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| US10526384B2 (en) * | 2012-11-19 | 2020-01-07 | Pieris Pharmaceuticals Gmbh | Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof |
| HK1213194A1 (zh) | 2013-03-14 | 2016-06-30 | Daiichi Sankyo Co., Ltd. | 用於新型的结合蛋白质pcsk9 |
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| WO2015177175A2 (en) * | 2014-05-22 | 2015-11-26 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| JP6839087B2 (ja) | 2015-01-28 | 2021-03-03 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 血管新生に特異的な新規のタンパク質 |
| CR20170425A (es) | 2015-02-18 | 2017-11-22 | Sanofi Sa | Nuevas proteínas específicas para pioverdina y pioquelina |
| JP6783797B2 (ja) * | 2015-05-04 | 2020-11-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 抗がん融合ポリペプチド |
| CN114573680A (zh) * | 2015-05-04 | 2022-06-03 | 皮里斯制药有限公司 | Cd137特异性的蛋白 |
| EP3298030B1 (en) * | 2015-05-18 | 2023-01-18 | Pieris Pharmaceuticals GmbH | Anti-cancer fusion polypeptide |
| MX2017014730A (es) | 2015-05-18 | 2018-06-28 | Pieris Pharmaceuticals Gmbh | Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3). |
| EP3115371A1 (en) * | 2015-07-07 | 2017-01-11 | Sanofi | Fusion molecules |
| WO2017009456A1 (en) * | 2015-07-15 | 2017-01-19 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for lag-3 |
| TW201725212A (zh) * | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| WO2018087108A1 (en) | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| CA3050194A1 (en) * | 2017-01-18 | 2018-07-26 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for lag-3 |
| FI3830120T3 (fi) * | 2018-07-31 | 2023-06-13 | Pieris Pharmaceuticals Gmbh | CD137:lle ja PD-L1:lle spesifinen uusi fuusioproteiini |
| US20210246219A1 (en) * | 2018-08-27 | 2021-08-12 | Pieris Pharmaceuticals Gmbh | Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof |
| SG11202106353VA (en) * | 2019-02-26 | 2021-07-29 | Pieris Pharmaceuticals Gmbh | Novel fusion proteins specific for cd137 and gpc3 |
| US20220193191A1 (en) * | 2019-03-29 | 2022-06-23 | Astrazeneca Ab | Lipocalin mutein for treatment of asthma |
| EP4161957A1 (en) * | 2020-06-05 | 2023-04-12 | Pieris Pharmaceuticals GmbH | Multimeric immunomodulator targeting 4-1bb |
| JP2023541482A (ja) * | 2020-09-18 | 2023-10-02 | ピエリス ファーマシューティカルズ ゲーエムベーハー | バイオマーカー法および使用法 |
-
2020
- 2020-03-27 EP EP20719569.4A patent/EP3946417A1/en not_active Withdrawn
- 2020-03-27 US US17/599,765 patent/US20220168387A1/en not_active Abandoned
- 2020-03-27 JP JP2021557778A patent/JP2022526367A/ja not_active Withdrawn
- 2020-03-27 KR KR1020217035440A patent/KR20210146999A/ko not_active Withdrawn
- 2020-03-27 WO PCT/EP2020/058637 patent/WO2020201038A1/en not_active Ceased
- 2020-03-27 CA CA3127973A patent/CA3127973A1/en active Pending
- 2020-03-27 CN CN202080025546.6A patent/CN113939307A/zh active Pending
- 2020-03-27 AU AU2020253034A patent/AU2020253034A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102325532B (zh) | 用于减轻肺部炎症的左氧氟沙星吸入剂 | |
| JP2021193091A (ja) | 疾患の処置のための鼻腔内エピネフリン製剤及び方法 | |
| US6297227B1 (en) | Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines | |
| AU2007298814B2 (en) | Galenic form for the trans-mucosal delivery of active ingredients | |
| TW470647B (en) | Composition and pharmaceutical combination kit comprising formoterol and budesonide | |
| JP2774379B2 (ja) | 医薬エアロゾール組成物ならびにそれらのウイルス疾患の治療および予防用途 | |
| JP2012522009A (ja) | 肺炎および人工呼吸器関連気管気管支炎を治療および予防するための方法 | |
| KR20110045004A (ko) | 충혈제거제 및 코르티코스테로이드를 포함하는 비강내 조성물 | |
| JP2022526367A5 (enExample) | ||
| WO2018017434A1 (en) | Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces | |
| IL298659A (en) | Method for pulsatile delivery of a gaseous drug | |
| ME01494B (me) | Farmaceutska formulacija za liječenje gornjeg digestivnog trakta | |
| JP2008110991A (ja) | 処置方法 | |
| EP3678649B1 (en) | Intranasal epinephrine formulations and methods for the treatment of disease | |
| Gümrü et al. | Oral candidiasis as a local adverse effect of inhaled corticosteroids: what the dental practitioner should know | |
| JP2003040797A (ja) | 抗炎症性肺疾患およびａｒｄｓにおける抗トロンビン吸入のための医薬製剤 | |
| AU2013384129B2 (en) | Oral suspension for treating eosinophilic esophagitis | |
| JP2003513048A (ja) | 気道狭窄の治療のための酸化窒素の使用 | |
| WO2015009776A1 (en) | Low dose corticosteroid microemulsion compositions and methods of treatments thereof | |
| JP5220741B2 (ja) | アンドラスト／グルココルチコイドの併用 | |
| HK40121592A (en) | Intranasal epinephrine formulations and methods for the treatment of disease | |
| Mason | American Thoracic Society 2019 International Conference. Dallas, Texas, USA-May 17-22, 2019 | |
| DE102024001175A1 (de) | Zubereitung zur Behandlung von entzündlichen Erkrankungen der Atemwege. | |
| WO2021211854A1 (en) | Inhalable formulation of a solution containing tiotropium bromide | |
| WO2022005321A1 (en) | Inhaled tocilizumab for treating interleukin-6 related respiratory diseases |